Elevance Health (NYSE:ELV) Updates FY 2026 Earnings Guidance

Elevance Health (NYSE:ELV) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 26.750- for the period, compared to the consensus earnings per share estimate of 26.910. The company issued revenue guidance of -.

Elevance Health Price Performance

NYSE:ELV opened at $404.33 on Thursday. The firm has a market capitalization of $87.81 billion, a price-to-earnings ratio of 17.20, a PEG ratio of 2.40 and a beta of 0.67. The business has a 50 day simple moving average of $362.40 and a 200-day simple moving average of $343.89. Elevance Health has a 1 year low of $273.71 and a 1 year high of $426.98. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.48.

Elevance Health (NYSE:ELV) last posted its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 EPS for the quarter, topping the consensus estimate of $10.74 by $1.84. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The company had revenue of $49.49 billion during the quarter, compared to analyst estimates of $48.21 billion. During the same period in the previous year, the firm earned $11.97 earnings per share. Elevance Health’s quarterly revenue was up 1.5% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Equities analysts forecast that Elevance Health will post 26.94 EPS for the current year.

Elevance Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be paid a $1.72 dividend. This represents a $6.88 annualized dividend and a yield of 1.7%. The ex-dividend date of this dividend is Wednesday, June 10th. Elevance Health’s dividend payout ratio (DPR) is currently 29.26%.

Wall Street Analysts Forecast Growth

Several research firms have commented on ELV. Mizuho raised their price objective on Elevance Health from $435.00 to $465.00 and gave the stock an “outperform” rating in a report on Monday. Barclays upped their price objective on shares of Elevance Health from $408.00 to $480.00 and gave the company an “overweight” rating in a report on Tuesday, May 26th. Truist Financial boosted their price target on Elevance Health from $375.00 to $450.00 and gave the company a “buy” rating in a research note on Monday, June 1st. The Goldman Sachs Group increased their price objective on shares of Elevance Health from $350.00 to $370.00 and gave the stock a “neutral” rating in a research note on Friday, April 24th. Finally, Deutsche Bank Aktiengesellschaft raised Elevance Health from a “hold” rating to a “buy” rating and raised their target price for the stock from $363.00 to $498.00 in a report on Wednesday, May 20th. Fourteen research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $416.11.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP boosted its stake in Elevance Health by 25.2% during the 4th quarter. Wellington Management Group LLP now owns 8,289,976 shares of the company’s stock worth $2,906,051,000 after purchasing an additional 1,668,679 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Elevance Health by 27.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,446,185 shares of the company’s stock valued at $2,610,261,000 after buying an additional 1,607,274 shares during the last quarter. Invesco Ltd. lifted its stake in shares of Elevance Health by 22.9% in the third quarter. Invesco Ltd. now owns 2,597,488 shares of the company’s stock worth $839,300,000 after buying an additional 484,303 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in Elevance Health by 2.8% during the fourth quarter. The Manufacturers Life Insurance Company now owns 2,275,342 shares of the company’s stock worth $797,472,000 after acquiring an additional 61,472 shares during the last quarter. Finally, Hotchkis & Wiley Capital Management LLC boosted its position in Elevance Health by 44.2% during the third quarter. Hotchkis & Wiley Capital Management LLC now owns 2,045,480 shares of the company’s stock worth $660,935,000 after acquiring an additional 627,038 shares during the last quarter. Hedge funds and other institutional investors own 89.24% of the company’s stock.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.